Cullinan Oncology LLC

NASDAQ CGEM

Data sourced from

and

Download Data

Cullinan Oncology LLC Cash Dividend Coverage Ratio 2 year CAGR for the Trailing 12 Months (TTM) ending September 19, 2024

Cullinan Oncology LLC Cash Dividend Coverage Ratio 2 year CAGR is NA for the Trailing 12 Months (TTM) ending September 19, 2024. The cash dividend coverage ratio assesses a company's ability to cover its dividend payments with its operating cash flow. It is calculated by dividing operating cash flow by dividends paid. This ratio indicates the company's capacity to generate sufficient cash flow to support dividend distributions. A ratio greater than 1 indicates a healthy coverage of dividends, while a ratio less than 1 suggests potential challenges in meeting dividend obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

NASDAQ: CGEM

Cullinan Oncology LLC

CEO	Mr. Nadim Ahmed
IPO Date	Jan. 8, 2021
Location	United States
Headquarters	One Main Street, Cambridge, MA, United States, 02142
Employees	85
Sector	Healthcare
Industry	Biotechnology

Description

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Key trends